Quantcast

Latest Shire plc Stories

2014-09-24 23:02:25

Pharmaceutical Company Agrees to Pay U.S. and State Governments to Settle Off-Label Drug Marketing and False Claims Act Allegations Philadelphia, PA (PRWEB) September 24, 2014 Stephen A. Sheller of Sheller, P.C. announced today that Shire Pharmaceuticals, LLC has agreed to pay $58.9 million to resolve allegations by the Sheller whistleblower client that Shire violated the False Claims Act. Court documents detailing the civil allegations and settlement were signed by Shire and...

2014-09-24 16:26:15

PHILADELPHIA, September 24, 2014 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPG), today announced that it has reached a final agreement with the U.S. Attorney's Offices for the Eastern District of Pennsylvania and Northern District of Illinois, all 50 states and the District of Columbia to resolve a previously disclosed civil investigation of its sales and marketing practices for a period ending in 2010 relating to ADDERALL XR(R), VYVANSE(R) DAYTRANA(R), LIALDA(R) and...

2014-09-15 08:29:16

PHILADELPHIA, September 15, 2014 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPG), the global specialty biopharmaceutical company, announced today that the US Food and Drug Administration (FDA) has accepted for filing with priority review a supplemental New Drug Application (sNDA) for Vyvanse(R) (lisdexamfetamine dimesylate) Capsules (CII) as a treatment for adults with binge eating disorder (BED). The FDA is expected to provide a decision in February 2015, based on the...

2014-09-03 16:29:39

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION NORTH CHICAGO, Ill., Sept. 3, 2014 /PRNewswire/ -- Following the announcement of the collaboration agreements with Calico Life Sciences LLC (Calico) and Infinity Pharmaceuticals Inc (Infinity), AbbVie is amending its earnings guidance on a GAAP basis for the year ending...

2014-08-18 12:26:52

DUBLIN, Aug. 18, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "Global Lysosomal Storage Diseases Market 2014-2018" report to their offering. http://photos.prnewswire.com/prnvar/20130307/600769 The term lysosomal storage diseases refers to a group of rare inherited disorders caused by the deficiency of lysosomal enzymes, activator proteins, proteins required for normal post-translational modification of lysosomal enzymes or proteins required for intracellular...

2014-07-25 08:25:24

- Reports Second-Quarter Adjusted EPS of $0.82, Above Previous Guidance Range of $0.75 to $0.77 (Reports GAAP EPS of $0.68) NORTH CHICAGO, Ill., July 25, 2014 /PRNewswire/ -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION AbbVie (NYSE:ABBV) today announced financial results for the second quarter ended June 30,...

2014-07-23 08:30:41

Strengthens Leadership Position in Treatments for Hunter syndrome and Commitment to MPS II Patient Community LEXINGTON, Massachusetts, July 23, 2014 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPG), the global specialty biopharmaceutical company, and ArmaGen, a US privately held biotechnology company, today announced a worldwide licensing and collaboration agreement for AGT-182, an investigational enzyme replacement therapy (ERT) for the potential treatment of both the...

2014-07-23 08:30:28

ArmaGen to Receive up to Approximately $225 Million Including Initial Upfront Payment of $15 Million in Cash and Equity, an Additional Equity Investment, R&D Funding, Development and Sales Milestones, in Addition to Future Royalties CALABASAS, Calif., July 23, 2014 /PRNewswire/ -- ArmaGen, a privately held biotechnology company focused on developing revolutionary therapies to treat severe neurological disorders, announced today that it has entered into a worldwide licensing and...

2014-07-18 08:23:58

Infographic containing information about the recommended combination of AbbVie Inc. ("AbbVie") with Shire plc ("Shire") NORTH CHICAGO, Ill., July 18, 2014 /PRNewswire/ -- On July 18, 2014, AbbVie issued an infographic highlighting AbbVie and Shire's complementary fit and the benefits of the proposed combination. A copy of the infographic materials will be available on AbbVie's website at: http://www.abbvieinvestor.com/phoenix.zhtml?c=251551&p=irol-disclaimer-documents In...

2014-07-17 16:25:39

LEXINGTON, Massachusetts, July 17, 2014 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPG) today announced top-line results from two Phase 4 efficacy and safety studies of Vyvanse(R) (lisdexamfetamine dimesylate) compared with Concerta (methylphenidate HCl) with a placebo reference arm in adolescents aged 13-17 diagnosed with Attention-Deficit/Hyperactivity Disorder (ADHD). In SPD489-406, the forced-dose titration study, Vyvanse was found to be statistically superior to...


Word of the Day
cacodemon
  • An evil spirit; a devil.
  • A nightmare.
  • In astrology, the twelfth house of a scheme or figure of the heavens: so called from its signifying dreadful things, such as secret enemies, great losses, imprisonment, etc.
'Cacodemon' comes from a Greek term meaning 'evil genius.'
Related